Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3732)	5/10/2001 3:10:59 PM
From: opalapril	Respond to of 52153

How *does* this happen with a very few - but not most? Don't tell me it's special treatment for life threatening indications; PFE's Viagra got similar red-carpet treatment. "The FDA said it reviewed Novartis' application for approval in less than three months, a remarkably short period for such approvals. The drug is expected to be available by the end of the month." siliconinvestor.com

To: Biomaven who wrote (3732)	5/10/2001 3:37:21 PM
From: Davy Crockett	Read Replies (2) \| Respond to of 52153

Why?????? Please explain. What's wrong with that? Get a life... maybe u can afford one? Peter

To: Biomaven who wrote (3732)	5/10/2001 8:22:20 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<Only wish it had been a biotech rather than a big bad pharma that had delivered this revolutionary drug...>> Gleevec isn't as revolutionary new cancer drug as it is sub-specific for cancer type where one gene went wrong. Definitely it is a very potent drug for CML, but media and street will overdue as they usually do. The point is that specific and selective targeting is way to treat cancer, however and unfortunately very few cancer type have this characteristic. Miljenko